Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 51 for your search:

Cancer Type/Condition:  Esophageal cancer
Stage/Subtype:  stage III esophageal cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16-00017, NCT00754468

Phase III Randomized Study of Chemoradiotherapy Comprising Paclitaxel, Cisplatin, and Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Esophageal Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0436, RTOG 0436, NCT00655876

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901

A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 0806009855, NCT00760604

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2004-0290, NCT00526110

An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AT-101-CS-102, NCT00561197

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07326, NCT00667420

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060317, NCT00719550

10.

Phase I/II Randomized Study of Vandetanib, Oxaliplatin, and Docetaxel in Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-6507, CASE6507, SANOFI-AVENTIS-CASE-6507, NCT00732745

11.

Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MBP-426 201, NCT00964080

12.

Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3G-03-5, NCT00183872

13.

Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3G-03-4, NCT00183898

14.

Phase II Study of Neoadjuvant Cisplatin and Irinotecan Hydrochloride (CI) Followed by Chemoradiotherapy Comprising CI and Radiotherapy in Patients With Resectable Esophageal or Gastroesophageal Junction Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-80302, NCT00316862

15.

Phase II Study of Neoadjuvant Irinotecan Hydrochloride, Cisplatin, Bevacizumab, and Radiotherapy Followed By Surgery and Adjuvant Bevacizumab in Patients With Locally Advanced Adenocarcinoma of the Esophagus

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06013, NCT00354679

16.

Phase II Study of Docetaxel, Cisplatin, Fluorouracil, Leucovorin Calcium, and Bevacizumab in Patients With Locally Recurrent, Unresectable, or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06096, NCT00403468

17.

Phase II Study of Neoadjuvant Paclitaxel, Cisplatin, Gefitinib, and Radiotherapy Followed by Surgery and Adjuvant Gefitinib in Patients With Resectable, Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025

18.

Phase II Study of Erlotinib Hydrochloride and Radiotherapy in Older Patients With Stage I-IV Squamous Cell Carcinoma or Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: NCI
Protocol IDs: RPCI-I-62705, I 62705, NCT00524121

19.

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) With Growth Factor Support in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-103, NCT00515411

20.

Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: BrUOG-E-215, NCT00522795

21.

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and GEJ

Phase: Phase II
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: 2003-0769, NCT00525785

22.

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004-0703, NCT00525915

23.

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LPT109747, NCT00526669

24.

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CC#064511, NCT00539617

25.

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UMCC 2006.117, NCT00570531

Select All on Page

Help with Results

A Service of the National Cancer Institute